

Assistant Commissioner for Patents Washington, D.C. 20231

On June 26, 2001

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Holten-Andersen, Mads et al

Application No.: 09/546,573

Filed: April 10, 2000

For: TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER

Examiner: Rawlings, S.

Art Unit:

1642

SUPPLEMENTAL INFORMATION **DISCLOSURE STATEMENT UNDER 37**

CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Search/Examination report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and Holten-Andersen, Mads et al. Application No.: 09/546,573

Page 2

no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the abovenoted Deposit Account.

Respectfully submitted,

Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

KLB:jrc

SF 1240697 v1